P
Paolo Cravedi
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 246
Citations - 7530
Paolo Cravedi is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Kidney transplantation. The author has an hindex of 39, co-authored 205 publications receiving 5684 citations. Previous affiliations of Paolo Cravedi include Mario Negri Institute for Pharmacological Research & Vita-Salute San Raffaele University.
Papers
More filters
Journal ArticleDOI
Long-Term Outcome of Renal Transplantation from Older Donors
Giuseppe Remuzzi,Paolo Cravedi,Annalisa Perna,Borislav D. Dimitrov,Marta Turturro,Giuseppe Locatelli,Paolo Rigotti,Nicola Baldan,M Beatini,Umberto Valente,Mario Scalamogna,Piero Ruggenenti +11 more
TL;DR: The long-term survival of single or dual kidney grafts from donors older than 60 years of age is excellent, provided that the grafts are evaluated histologically before implantation.
Journal ArticleDOI
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium.
Paolo Cravedi,Suraj Sarvode Mothi,Yorg Azzi,Meredith Haverly,Samira S. Farouk,María José Pérez-Sáez,María Dolores Redondo-Pachón,Barbara Murphy,Sander Florman,Laura Goldfarb Cyrino,Monica Grafals,Sandheep Venkataraman,Xingxing S. Cheng,Aileen X. Wang,Gianluigi Zaza,Andrea Ranghino,Lucrezia Furian,Joaquin Manrique,Umberto Maggiore,Ilaria Gandolfini,Nikhil Agrawal,Het Patel,Enver Akalin,Leonardo V. Riella +23 more
TL;DR: Hospitalized kidney transplant recipients with COVID‐19 have higher rates of acute kidney injury and mortality, and predictors of poor clinical outcomes were determined through multivariable analyses.
Journal ArticleDOI
Rituximab in Idiopathic Membranous Nephropathy
Piero Ruggenenti,Paolo Cravedi,Antonietta Chianca,Annalisa Perna,Barbara Ruggiero,Flavio Gaspari,Alessandro Rambaldi,Maddalena Marasa,Giuseppe Remuzzi +8 more
TL;DR: Rituximab achieved disease remission and stabilized or improved renal function in a large cohort of high-risk patients with IMN, and the magnitude of proteinuria reduction significantly correlated with slower GFR decline.
Journal ArticleDOI
The RAAS in the pathogenesis and treatment of diabetic nephropathy
TL;DR: A study in patients with type 1 diabetes and overt nephropathy found that RAAS inhibition with angiotensin-converting-enzyme (ACE) inhibitors was associated with a reduced risk of progression to end-stage renal disease and mortality compared with non-RAAS-inhibiting drugs.
Journal ArticleDOI
Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs
Marina Noris,Federica Casiraghi,Marta Todeschini,Paolo Cravedi,Daniela Cugini,Giuseppe Monteferrante,Sistiana Aiello,Linda Cassis,Eliana Gotti,Flavio Gaspari,Dario Cattaneo,Norberto Perico,Giuseppe Remuzzi +12 more
TL;DR: Findings from this study will be instrumental in developing "tolerance permissive" immunosuppressive regimens in the clinical setting of renal transplant patients.